Persistent Asset Partners’s UroGen Pharma URGN Stock Holding History

Persistent Asset Partners’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$65.9K	Sell	1,790 -4,034	-69%	-$109K	0.02%	387
2026 Q1	$105K	Sell	5,824 -6,982	-55%	-$140K	0.04%	235
2025 Q4	$300K	Sell	12,806 -7,920	-38%	-$172K	0.13%	184
2025 Q3	$413K	Sell	20,726 -13,874	-40%	-$249K	0.28%	93
2025 Q2	$474K	Buy	34,600 +17,029	+97%	+$163K	0.35%	80
2025 Q1	$194K	Buy	+17,571	New	+$187K	0.16%	100

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Persistent Asset Partners's URGN Position: Q2 2026 in Review

Persistent Asset Partners reduced its UroGen Pharma (URGN) stake by 69% in Q2 2026, selling an estimated $109K and leaving 1,790 shares worth $65.9K. The position accounts for 0.02% of the portfolio, ranked #387.

Persistent Asset Partners first reported a position in URGN in Q1 2025 and has held it in 6 quarters since. The position peaked at $474K in Q2 2025. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Persistent Asset Partners held 1,790 shares of UroGen Pharma worth $65.9K as of Q2 2026.
Persistent Asset Partners sold 4,034 UroGen Pharma shares in Q2 2026, an estimated $109K.
UroGen Pharma made up 0.02% of Persistent Asset Partners's portfolio in Q2 2026, its #387 holding.
Persistent Asset Partners first reported a position in UroGen Pharma in Q1 2025 and has held it in 6 quarters since.
Persistent Asset Partners's UroGen Pharma position peaked at $474K in Q2 2025.
189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.